These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 23611272)

  • 1. [Molecular and histologic characteristics of secondary imatinib-resistant gastrointestinal stromal tumors].
    Zheng S; Jia J; Pan YL; Tao DY; Lu HS
    Zhonghua Bing Li Xue Za Zhi; 2013 Jan; 42(1):42-3. PubMed ID: 23611272
    [No Abstract]   [Full Text] [Related]  

  • 2. [Chemotherapy and target-therapy of gastrointestinal tumors call for development of pathology].
    Shen L
    Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):438-9. PubMed ID: 17845753
    [No Abstract]   [Full Text] [Related]  

  • 3. [KIT mutation analysis in pathological diagnosis and target-therapy of gastrointestinal stromal tumors: an update].
    Chen LR
    Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):440-3. PubMed ID: 17845754
    [No Abstract]   [Full Text] [Related]  

  • 4. Secondary resistance to imatinib mesylate in a patient with unresectable duodenal GIST without mutations in exons 9, 11, 13, or 17 of the c-kit protooncogene.
    Yamaguchi M; Matsumoto T; Tate G; Higuchi T
    J Gastroenterol; 2004 Sep; 39(9):904-5. PubMed ID: 15565413
    [No Abstract]   [Full Text] [Related]  

  • 5. [Chinese consensus in diagnosis and treatment of gastrointestinal stromal tumor].
    Chinese Diagnosis and Treatment Experts Group for Gastrointestinal Stromal Tumors
    Zhonghua Bing Li Xue Za Zhi; 2009 Oct; 38(10):697-702. PubMed ID: 20078976
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of imatinib mesylate in a patient with a metastatic gastrointestinal stromal tumor with a c-kit mutation in exon 11.
    Kubota K; Katayama A; Takeshita Y; Nozaki K; Ueda T; Imamura K; Hiki N; Nomura S; Kaminishi M; Mafune K
    Dig Dis Sci; 2007 Jul; 52(7):1725-9. PubMed ID: 17546507
    [No Abstract]   [Full Text] [Related]  

  • 7. Advanced or metastatic gastrointestinal stromal tumors: systemic treatment options.
    Caram MV; Schuetze SM
    J Surg Oncol; 2011 Dec; 104(8):888-95. PubMed ID: 22069173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surgical intervention for imatinib and sunitinib-resistant gastrointestinal stromal tumors.
    Kikuchi H; Setoguchi T; Miyazaki S; Yamamoto M; Ohta M; Kamiya K; Sakaguchi T; Konno H
    Int J Clin Oncol; 2011 Dec; 16(6):741-5. PubMed ID: 21394667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imatinib plasma monitoring-guided dose modification for managing imatinib-related toxicities in gastrointestinal stromal tumor patients.
    Yoon S; Ryu MH; Yoo C; Beck MY; Ryoo BY; Kang YK
    J Korean Med Sci; 2013 Aug; 28(8):1248-52. PubMed ID: 23960456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Study on the mechanism of imatinib-induced resistance in gastrointestinal stromal tumors].
    Zhou Y; Hou YY; Tan YS; Lu SH; Hou J; Liu JL; Qin J; Shen KT; Sun YH
    Zhonghua Zhong Liu Za Zhi; 2009 Aug; 31(8):597-601. PubMed ID: 20021947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rare, germline mutation of KIT with imatinib-resistant multiple GI stromal tumors and mastocytosis.
    Speight RA; Nicolle A; Needham SJ; Verrill MW; Bryon J; Panter S
    J Clin Oncol; 2013 Jun; 31(16):e245-7. PubMed ID: 23610110
    [No Abstract]   [Full Text] [Related]  

  • 12. [Consensus on the medical treatment of gastrointestinal stromal tumors].
    Zhonghua Zhong Liu Za Zhi; 2007 Nov; 29(11):875-7. PubMed ID: 18396652
    [No Abstract]   [Full Text] [Related]  

  • 13. [Carney triad: clinicopathologic study of 2 cases with molecular analysis].
    Xu C; Hou YY; Qi WD; Lu SH; Hou J; Tan YS; Qin J; Sun YH
    Zhonghua Bing Li Xue Za Zhi; 2009 Sep; 38(9):626-7. PubMed ID: 20079194
    [No Abstract]   [Full Text] [Related]  

  • 14. Correlation of imatinib resistance with the mutational status of KIT and PDGFRA genes in gastrointestinal stromal tumors: a meta-analysis.
    Lee JH; Kim Y; Choi JW; Kim YS
    J Gastrointestin Liver Dis; 2013 Dec; 22(4):413-8. PubMed ID: 24369323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gastrointestinal stromal tumor and its targeted therapeutics.
    Dupart J; Zhang W; Trent JC
    Chin J Cancer; 2011 May; 30(5):303-14. PubMed ID: 21527063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations.
    Wardelmann E; Thomas N; Merkelbach-Bruse S; Pauls K; Speidel N; Büttner R; Bihl H; Leutner CC; Heinicke T; Hohenberger P
    Lancet Oncol; 2005 Apr; 6(4):249-51. PubMed ID: 15811621
    [No Abstract]   [Full Text] [Related]  

  • 17. [Gastrointestinal stromal tumor of small intestine associated with lymph node metastasis: a report of 2 cases with review of literatures].
    Kong M; Wang YL; Xu LJ; Teng XD
    Zhonghua Bing Li Xue Za Zhi; 2009 Sep; 38(9):617-20. PubMed ID: 20079191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secondary mutations of c-KIT contribute to acquired resistance to imatinib and decrease efficacy of sunitinib in Chinese patients with gastrointestinal stromal tumors.
    Gao J; Tian Y; Li J; Sun N; Yuan J; Shen L
    Med Oncol; 2013 Jun; 30(2):522. PubMed ID: 23456621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging characteristics of liver metastasis from gastrointestinal stromal tumor before and after imatinib mesylate treatment.
    Ulusan S; Koç Z; Kayaselçuk F
    Turk J Gastroenterol; 2008 Jun; 19(2):129-32. PubMed ID: 19110671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Establishment and pathologic analysis of imatinib-resistant gastrointestinal stromal tumor xenografts].
    Zheng S; Wang XJ; Jia J; Pan YL; Tao DY; Lu HS; Huang KE
    Zhonghua Bing Li Xue Za Zhi; 2012 Mar; 41(3):176-80. PubMed ID: 22800481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.